Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free ENSC Stock Alerts

Ensysce Biosciences (ENSC) Competitors

Ensysce Biosciences logo
$0.40 +0.04 (+11.63%)
Closing price 04:00 PM Eastern
Extended Trading
$0.40 0.00 (-0.25%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ENSC vs. PLRZ, PSTV, CTXR, VYNE, and SCNX

Should you buy Ensysce Biosciences stock or one of its competitors? Ensysce Biosciences's main competitors and comparable companies include Polyrizon (PLRZ), Plus Therapeutics (PSTV), Citius Pharmaceuticals (CTXR), VYNE Therapeutics (VYNE), and Scienture (SCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ensysce Biosciences compare to Polyrizon?

Ensysce Biosciences (NASDAQ:ENSC) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Polyrizon has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Polyrizon's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-280.53% -2,550.30% -320.49%
Polyrizon N/A N/A N/A

5.6% of Ensysce Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ensysce Biosciences has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market.

In the previous week, Ensysce Biosciences had 3 more articles in the media than Polyrizon. MarketBeat recorded 8 mentions for Ensysce Biosciences and 5 mentions for Polyrizon. Ensysce Biosciences' average media sentiment score of 0.67 beat Polyrizon's score of 0.66 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ensysce Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Polyrizon
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Polyrizon
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Polyrizon has lower revenue, but higher earnings than Ensysce Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M1.55-$10.18M-$2.76N/A
PolyrizonN/AN/A-$3.34MN/AN/A

Summary

Ensysce Biosciences beats Polyrizon on 6 of the 10 factors compared between the two stocks.

How does Ensysce Biosciences compare to Plus Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Ensysce Biosciences has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M1.55-$10.18M-$2.76N/A
Plus TherapeuticsN/AN/A-$22.39M-$2.30N/A

In the previous week, Ensysce Biosciences had 7 more articles in the media than Plus Therapeutics. MarketBeat recorded 8 mentions for Ensysce Biosciences and 1 mentions for Plus Therapeutics. Ensysce Biosciences' average media sentiment score of 0.67 beat Plus Therapeutics' score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ensysce Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Plus Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ensysce Biosciences has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Plus Therapeutics has a consensus target price of $51.75, suggesting a potential upside of 1,648.31%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Plus Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Plus Therapeutics has a net margin of -230.24% compared to Ensysce Biosciences' net margin of -280.53%. Plus Therapeutics' return on equity of -198.48% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-280.53% -2,550.30% -320.49%
Plus Therapeutics -230.24%-198.48%-73.13%

Summary

Plus Therapeutics beats Ensysce Biosciences on 8 of the 15 factors compared between the two stocks.

How does Ensysce Biosciences compare to Citius Pharmaceuticals?

Ensysce Biosciences (NASDAQ:ENSC) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Ensysce Biosciences has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Citius Pharmaceuticals has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Citius Pharmaceuticals' return on equity of -59.57% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-280.53% -2,550.30% -320.49%
Citius Pharmaceuticals N/A -59.57%-34.47%

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 728.23%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Ensysce Biosciences has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M1.55-$10.18M-$2.76N/A
Citius PharmaceuticalsN/AN/A-$37.43M-$1.67N/A

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Ensysce Biosciences. MarketBeat recorded 11 mentions for Citius Pharmaceuticals and 8 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.67 beat Citius Pharmaceuticals' score of -0.70 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ensysce Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Citius Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Summary

Citius Pharmaceuticals beats Ensysce Biosciences on 11 of the 15 factors compared between the two stocks.

How does Ensysce Biosciences compare to VYNE Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Ensysce Biosciences has a net margin of -280.53% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-280.53% -2,550.30% -320.49%
VYNE Therapeutics -4,726.21%-70.42%-63.46%

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ensysce Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Ensysce Biosciences has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M1.55-$10.18M-$2.76N/A
VYNE Therapeutics$570K33.29-$26.48M-$0.38N/A

In the previous week, Ensysce Biosciences had 8 more articles in the media than VYNE Therapeutics. MarketBeat recorded 8 mentions for Ensysce Biosciences and 0 mentions for VYNE Therapeutics. Ensysce Biosciences' average media sentiment score of 0.67 beat VYNE Therapeutics' score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Ensysce Biosciences Positive
VYNE Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
VYNE Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

VYNE Therapeutics beats Ensysce Biosciences on 7 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Scienture?

Ensysce Biosciences (NASDAQ:ENSC) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Ensysce Biosciences has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Scienture has a beta of 3.26, meaning that its share price is 226% more volatile than the broader market.

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 21.4% of Scienture shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ensysce Biosciences has higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M1.55-$10.18M-$2.76N/A
Scienture$430K39.46-$41.51M-$2.10N/A

Scienture has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Scienture's return on equity of -53.51% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-280.53% -2,550.30% -320.49%
Scienture N/A -53.51%-42.47%

Scienture has a consensus price target of $1.50, suggesting a potential upside of 263.02%. Given Scienture's stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scienture
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Ensysce Biosciences had 7 more articles in the media than Scienture. MarketBeat recorded 8 mentions for Ensysce Biosciences and 1 mentions for Scienture. Ensysce Biosciences' average media sentiment score of 0.67 beat Scienture's score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Ensysce Biosciences Positive
Scienture Neutral

Summary

Scienture beats Ensysce Biosciences on 11 of the 16 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENSC vs. The Competition

Export
MetricEnsysce BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.02M$12.54B$7.34B$12.72B
Dividend YieldN/A2.61%2.53%11.02%
P/E Ratio-0.15778.14270.9424.14
Price / Sales1.55754.40634.7796.69
Price / CashN/A98.0278.5753.12
Price / Book-6.7212.0213.146.25
Net Income-$10.18M$2.80B$3.46B$347.86M
7 Day Performance4.68%3.95%3.23%1.57%
1 Month Performance54.17%6.54%8.82%5.24%
1 Year Performance-80.34%8.76%27.70%17.87%

Ensysce Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENSC
Ensysce Biosciences
1.2566 of 5 stars		$0.40
+11.6%		N/A-82.4%$7.02M$5.07MN/A10
PLRZ
Polyrizon
0.9851 of 5 stars		$10.36
-5.6%		N/A+65.1%$22.88MN/AN/AN/A
PSTV
Plus Therapeutics
2.0232 of 5 stars		$3.20
-13.0%		$51.75
+1,517.2%		-74.7%$22.03MN/AN/A20
CTXR
Citius Pharmaceuticals
2.4307 of 5 stars		$0.57
+1.7%		$5.00
+774.4%		-57.4%$20.74MN/AN/A20
VYNE
VYNE Therapeutics
0.2914 of 5 stars		$28.33
-0.8%		N/A+69.6%$18.98M$570KN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENSC) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel